Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | Unknown | — |
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | Unknown | IM |
RabAvert was infiltrated in the patient´s finger/injected Rabavert directly into the wound; Case reference number US-BN-2026-000700 is a spontaneous case initially received from a pharmacist on 30-Apr-2026 via Bavarian Nordic (reference number: CASE-2026-000615) and concerns a male patient of an unknown age. The patient's current medical history and concomitant medication details were not provided. The patient's concurrent medical history included wound. On an unspecified date, (reported as in last two months, early April or late March), the patient received first dose of RabAvert along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution of (batch number: unknown), at unknown dose, route of administration, in fingers directly into the wound for post-exposure prophylaxis (explicitly coded as 'vaccine administered at inappropriate site'). On unspecified date, the administration was given correctly after this incident. No health issues have been reported by the patient after administration mistake and correction. On an unspecified date, (reported as in last two months), the patient received a dose of immunoglobulin Kedrab, at unknown dose, route of administration, and site of administration were unknown for post-exposure prophylaxis. At the time of initial, it was unknown if the patient experienced any adverse event due to the RabAvert vaccination. No further information was provided.; Reporter's Comments: This spontaneous case concerns a male patient of an unknown age who received the first dose RabAvert vaccine for post-exposure prophylaxis in fingers directly into the wound (explicitly coded as 'vaccine administered at inappropriate site'). On an unspecified date, the administration was given correctly after this incident. At the time of initial report, it was unknown if the patient experienced any adverse event due to the RabAvert vaccination. Product administered at inappropriate site is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administered at inappropriate site is considered not related to the suspect vaccine but to a human factor. This case is considered as non-serious. For regulatory reporting purposes, this case is considered not related.; Sender's Comments: This spontaneous case concerns a male patient of an unknown age who received the first dose RabAvert vaccine for post-exposure prophylaxis in fingers directly into the wound (explicitly coded as 'vaccine administered at inappropriate site'). On an unspecified date, the administration was given correctly after this incident. At the time of initial report, it was unknown if the patient experienced any adverse event due to the RabAvert vaccination. Product administered at inappropriate site is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administered at inappropriate site is considered not related to the suspect vaccine but to a human factor. This case is considered as non-serious. For regulatory reporting purposes, this case is considered not related.
Wound